BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 19652665)

  • 1. Urine markers in monitoring for prostate cancer.
    Jamaspishvili T; Kral M; Khomeriki I; Student V; Kolar Z; Bouchal J
    Prostate Cancer Prostatic Dis; 2010 Mar; 13(1):12-9. PubMed ID: 19652665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer.
    Hessels D; Smit FP; Verhaegh GW; Witjes JA; Cornel EB; Schalken JA
    Clin Cancer Res; 2007 Sep; 13(17):5103-8. PubMed ID: 17785564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progensa™ PCA3 test for prostate cancer.
    Durand X; Moutereau S; Xylinas E; de la Taille A
    Expert Rev Mol Diagn; 2011 Mar; 11(2):137-44. PubMed ID: 21405964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical applications of molecular biomarkers in prostate cancer detection.
    Dumache R; Miclea F; Bumblăcilă B; Puiu M
    Rev Med Chir Soc Med Nat Iasi; 2010; 114(2):470-5. PubMed ID: 20700989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer.
    Cao DL; Ye DW; Zhang HL; Zhu Y; Wang YX; Yao XD
    Prostate; 2011 May; 71(7):700-10. PubMed ID: 20957673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efforts to resolve the contradictions in early diagnosis of prostate cancer: a comparison of different algorithms of sarcosine in urine.
    Cao DL; Ye DW; Zhu Y; Zhang HL; Wang YX; Yao XD
    Prostate Cancer Prostatic Dis; 2011 Jun; 14(2):166-72. PubMed ID: 21321584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination of urine DD3(PCA3) mRNA and PSA mRNA as molecular markers of prostate cancer.
    Mearini E; Antognelli C; Del Buono C; Cochetti G; Giannantoni A; Nardelli E; Talesa VN
    Biomarkers; 2009 Jun; 14(4):235-43. PubMed ID: 19489685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion.
    Salagierski M; Schalken JA
    J Urol; 2012 Mar; 187(3):795-801. PubMed ID: 22245323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection.
    Schostak M; Schwall GP; Poznanović S; Groebe K; Müller M; Messinger D; Miller K; Krause H; Pelzer A; Horninger W; Klocker H; Hennenlotter J; Feyerabend S; Stenzl A; Schrattenholz A
    J Urol; 2009 Jan; 181(1):343-53. PubMed ID: 19012935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen.
    Fradet Y
    Curr Opin Urol; 2009 May; 19(3):243-6. PubMed ID: 19325493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quadriplex model enhances urine-based detection of prostate cancer.
    Jamaspishvili T; Kral M; Khomeriki I; Vyhnankova V; Mgebrishvili G; Student V; Kolar Z; Bouchal J
    Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):354-60. PubMed ID: 21788966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer.
    Woodson K; O'Reilly KJ; Hanson JC; Nelson D; Walk EL; Tangrea JA
    J Urol; 2008 Feb; 179(2):508-11; discussion 511-2. PubMed ID: 18076912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?
    Ploussard G; Haese A; Van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Bastien L; Abbou CC; Remzi M; Tinzl M; Feyerabend S; Stillebroer AB; Van Gils MP; Schalken JA; de La Taille A
    BJU Int; 2010 Oct; 106(8):1143-7. PubMed ID: 20230386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA methylation biomarkers of prostate cancer: confirmation of candidates and evidence urine is the most sensitive body fluid for non-invasive detection.
    Payne SR; Serth J; Schostak M; Kamradt J; Strauss A; Thelen P; Model F; Day JK; Liebenberg V; Morotti A; Yamamura S; Lograsso J; Sledziewski A; Semjonow A
    Prostate; 2009 Sep; 69(12):1257-69. PubMed ID: 19459176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis.
    Rostad K; Hellwinkel OJ; Haukaas SA; Halvorsen OJ; Øyan AM; Haese A; Budäus L; Albrecht H; Akslen LA; Schlomm T; Kalland KH
    APMIS; 2009 Aug; 117(8):575-82. PubMed ID: 19664128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New tests for prostate cancer may be nearing the clinic.
    Tuma RS
    J Natl Cancer Inst; 2010 Jun; 102(11):752-4. PubMed ID: 20498428
    [No Abstract]   [Full Text] [Related]  

  • 17. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance.
    Nakanishi H; Groskopf J; Fritsche HA; Bhadkamkar V; Blase A; Kumar SV; Davis JW; Troncoso P; Rittenhouse H; Babaian RJ
    J Urol; 2008 May; 179(5):1804-9; discussion 1809-10. PubMed ID: 18353398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Prostate Cancer gene 3 assay: indications for use in clinical practice.
    Schilling D; de Reijke T; Tombal B; de la Taille A; Hennenlotter J; Stenzl A
    BJU Int; 2010 Feb; 105(4):452-5. PubMed ID: 19930176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy.
    Bastian PJ; Palapattu GS; Lin X; Yegnasubramanian S; Mangold LA; Trock B; Eisenberger MA; Partin AW; Nelson WG
    Clin Cancer Res; 2005 Jun; 11(11):4037-43. PubMed ID: 15930338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours.
    Jentzmik F; Stephan C; Miller K; Schrader M; Erbersdobler A; Kristiansen G; Lein M; Jung K
    Eur Urol; 2010 Jul; 58(1):12-8; discussion 20-1. PubMed ID: 20117878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.